ZHAOKE OPHTH-B(06622): The National Medical Products Administration has accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops) for the treatment of progressive myopia in children.

ZHAOKE OPHTH-B (06622) announced that the China National Medical Products Administration recently accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops), one of the company's core products used to treat progressive myopia in children. The new drug application is classified as a Class II innovative drug. Earlier on January 2, 2025, the company announced that the Chinese National Medical Products Administration had accepted a simplified new drug application for NVK002 (0.01% atropine sulfate eye drops) for the treatment of progressive myopia in children. The drug is currently undergoing the review process.